Progress in Neuro-Psychopharmacology and Biological Psychiatry
Review articleThe influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments
Introduction
Affective disorders have a large impact on social health, with considerable both direct and indirect costs (Bauwens et al., 1991, Pincus and Pettit, 2001, Rice, 1999).
Pharmacologic treatment of mood disorders reduced morbidity of depressive disorder and improved mental health for millions of individuals worldwide. Antidepressant drugs (AD), available since the early 1950s, improved well-being and increased the chance of a good long term outcome. From the late eighties, also other non-pharmacological treatments, such as sleep deprivation (SD), have proved their efficacy, both as the only and as augmentation therapy, in addition to ADs (Benedetti et al., 1997, Benedetti et al., 1999a, Benedetti et al., 2001, Smeraldi et al., 1999, Szuba et al., 1994, Vogel et al., 1980, Wirz-Justice and Van den Hoofdakker, 1999, Wu and Bunney, 1990). Unfortunately, not all subjects benefit from treatments, 30–40% of all patients do not respond sufficiently to the initial treatment and it takes up to 6 weeks for them to be identified (Doris et al., 1999). Efficient clinical predictors have not yet been established, but there is some evidence suggesting that genetic factors play a substantial role (Berrettini, 1998, Franchini et al., 1998, O'Reilly et al., 1994, Orsini, 1987, Pare and Mack, 1971, Sederer, 1986, Serretti et al., 1998).
Pharmacogenetics is the use of genetic information to guide pharmacotherapy by providing individualized and science-based treatment decisions. This field gained increasing attention and holds great promises for clinical medicine in the latest years (Dettling et al., 2001, Pickar and Rubinow, 2001, Roses, 2000, Segman et al., 1999). The emerging field of pharmacogenetics holds great potential, particularly in psychiatry, for refining and optimizing psychopharmacology, given the lack of biologically based treatment guidelines (American Psychiatric Association, 1994, American Psychiatric Association, 1997, American Psychiatric Association, 2000).
Beyond clinical factors, individual's variability in treatment response may be a result of the combination of polymorphisms in metabolic enzymes and in targeted receptors, in fact single gene mutations are unlikely to cause the continuous variability observed in response to psychiatric treatment (Pickar and Rubinow, 2001).
5HT is found in clustered neuronal cell bodies specifically located in the brainstem. The axons of these cells, however, innervate almost every area of the central nervous system, where 5HT has a variety of functions. Beside its fundamental role in mood tone, in fact, it is also involved in eating, sleeping, sexual behavior, the circadian cycle, and other neuro-endocrine functions, all involved in the clinical presentation of mood disorders. Levels of serotonergic neurotransmission in the forebrain are a key to mood: high activity are associated with euphoria, low activity with dysphoria (Jacobs and Fornal, 1995, Maes and Meltzer, 1995). ADs are known to act on monoamine systems; in particular, the majority of them has shown some association with the increase of serotonin (5HT) levels in the inter-synaptic cleft or an interaction with 5HT receptors (Jacobs and Fornal, 1995, Maes and Meltzer, 1995). Moreover, the serotonergic pathway is the main target of SSRIs, the most widely used AD compounds. They interfere with the activity of the serotonin transporter (SERT), a reuptake molecule that removes serotonin from the synaptic cleft (Schafer, 1999). The most current versions of the serotonin model hypothesize that selective serotonin reuptake inhibitors are effective against depression not only for their acute effects on serotonergic transmission, but also for the long-term adaptive changes in monoamine neurotransmission arising from the chronic inhibition of serotonin reuptake (Leonard, 1996). In particular, while the acute effects could be ascribed to the inhibition of serotonin reuptake in dorsal raphe nucleus, to the activation of somatodendritic autoreceptor 5-HT1A and to the decrease of serotonin release, the long-term effects could be linked to the desensitization of the same 5-HT1A autoreceptor, with an increasing serotonin release, and consequently the higher serotonin concentration in terminal areas (Artigas et al., 1996, Bel and Artigas, 1993). Moreover, molecular and pharmacological studies showed that SSRIs are involved in the modification of cellular mechanisms following receptor activation. In particular, changes in protein kinase C, protein Kinase A and in other postsynaptic substrates have been observed (Bel and Artigas, 1993, Perez et al., 1991, Perez et al., 1995).
The present paper reviews the pharmacogenetic studies published to date, focusing the attention on the serotonergic pathway.
Section snippets
Serotonin metabolism: synthesis and catabolism
5HT is synthesized from tryptophan, after the active uptake of this amino-acid into the serotonergic neurons. Tryptophan is transformed in 5-hydroxy-tryptophan via tryptophan hydroxylase (TPH), then the enzyme l-aromatic amino-acid Decarboxylase (AADC) synthesizes 5HT.
The TPH gene, which codes for the rate-limiting enzyme of 5HT biosynthesis, has been cloned (Boularand et al., 1990) and mapped on 11p15.3–p14 (Craig et al., 1991). Studies on administration of N
Serotonergic pathway: receptors and intracellular transduction system
There are multiple subtypes of 5HT receptors, with varying affinity. 5HT receptors are categorized into seven main classes (5HT1–7), among which the 5-HT1 receptor is divided into subclasses (A, D, E, and F) on the basis of their pharmacological and biochemical properties. The 5HT1D receptor is further divided into two classes, 5HT1D alpha and 5HT1D beta, both of which are encoded by intronless genes; human 5HT1D beta receptor subtype is classed as “5HT1B receptor” for its similarity to murine
5HT transporter
The brain 5HT transporter (SERT) is the principal site of action of many ADs and may mediate behavioral and toxic effects of cocaine and amphetamines. Its role is to uptake 5HT into the pre-synaptic neuron, which thus terminates the synaptic actions and recycles it into the neurotransmitter pool. Ramamoorthy et al. (1993) identified and cloned a single gene encoding the human SERT, localized to chromosome 17q11.1–q12. The gene spans 31 kb and consists of 14 exons (Lesch et al., 1994). Heils et
Conclusion
Pharmacogenetic studies are certainly prone to some criticism, particularly for the small explained variances of analyzed polymorphisms and the difficulty to compare findings between independent studies. The mechanisms of action of antidepressants are supposed to involve several genes, and so they are likely to play a relatively minor role in therapeutic response; for example, they could affect particular depressive symptoms only. Further studies should take into account the associations with
Acknowledgements
The authors thank Paola Artioli for her help in writing the manuscript.
References (109)
- et al.
Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists
Trends Neurosci.
(1996) - et al.
Dopaminergic augmentation of sleep deprivation effects in bipolar depression
Psychiatry Res.
(2001) - et al.
Antidepressant effects of light therapy combined with sleep deprivation are influenced by a functional polymorphism within the promoter of the serotonin transporter gene
Biol. Psychiatry
(2003) Progress and pitfalls: bipolar molecular linkage studies
J. Affect. Disord.
(1998)- et al.
The functional role of monoamine oxidases A and B in the mammalian central nervous system
Prog. Neurobiol.
(1994) - et al.
Current advances and trends in the treatment of depression
Trends Pharmacol. Sci.
(1994) - et al.
Total sleep deprivation combined with lithium and light therapy in the treatment of bipolar depression: replication of main effects and interaction
Psychiatry Res.
(2000) - et al.
Depressive illness
Lancet
(1999) - et al.
Chronic fluoxetine induces opposite changes in G protein coupling at pre and postsynaptic 5-HT(1A) receptors in rat brain
Neuropharmacology
(2003) - et al.
Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees
J. Psychiatr. Res.
(1998)
Effects of sleep deprivation on serotonergic neuronal activity in the dorsal raphe nucleus of the freely moving cat
Neuropsychopharmacology
Functional effects of chronic electroconvulsive shock on serotonergic 5-HT(1A) and 5-HT(1B) receptor activity in rat hippocampus and hypothalamus
Brain Res.
Serotonin transporter and seasonal variation in blood serotonin in families with obsessive-compulsive disorder
Neuropsychopharmacology
Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo
Life Sci.
A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine
Psychiatry Res.
Characterization of acute N-ethyl-3,4-methylenedioxyamphetamine (MDE) action on the central serotonergic system
Biochem. Pharmacol.
Effect of sunlight and season on serotonin turnover in the brain
Lancet
Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression
Neurosci. Lett.
Heterotrimeric G proteins: organizers of transmembrane signals
Cell
Sequence, splice site and population frequency distribution analyses of the polymorphic human tryptophan hydroxylase intron 7
Brain Res. Mol. Brain Res.
Pharmacogenetic response to antidepressants in a multicase family with affective disorder
Biol. Psychiatry
Effects of fluvoxamine on the protein phosphorylation system associated with rat neuronal microtubules
Eur. Neuropsychopharmacol.
Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment
Lancet
Pharmacogenomics of psychiatric disorders
Trends Pharmacol. Sci.
Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression
Neuropsychopharmacology
Toward a molecular architecture of personality
Behav. Brain Res.
How do antidepressants work? Prospects for genetic analysis of drug mechanisms
Cell
Tryptophan hydroxylase gene associated with paroxetine antidepressant activity
Eur. Neuropsychopharmacol.
SSRIs antidepressant activity is influenced by Gbeta3 variants
Eur. Neuropsychopharmacol.
Factors affecting the distribution of age at onset in patients with affective disorders
J. Psychiatr. Res.
Sustained antidepressant effect of sleep deprivation combined with pindolol in bipolar depression—a placebo-controlled trial
Neuropsychopharmacology
Serotonin transporter promoter genotype and illness recurrence in mood disorders
Eur. Neuropsychopharmacol.
Assignment of a serotonin 5HT-2 receptor gene (HTR2) to human chromosome 13q14–q21 and mouse chromosome 14
Genomics
Lithium sustains the acute antidepressant effects of sleep deprivation: preliminary findings from a controlled study
Psychiatry Res.
No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment
Eur. Neuropsychopharmacol.
Treatment of cycling female rats with fluoxetine induces desensitization of hypothalamic 5-HT(1A) receptors with no change in 5-HT(2A) receptors
Neuropharmacology
Sleep deprivation in depression: what do we know, where do we go?
Biol. Psychiatry
Practice guideline for the treatment of patients with bipolar disorder. American Psychiatric Association
Am. J. Psychiatry
Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association
Am. J. Psychiatry
Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association
Am. J. Psychiatry
Genetic variability in the promoter region of the serotonin transporter gene is associated with clinical remission of major depression after long term treatment with citalopram World Federation of societies of Biological Psychiatry
Association between serotoninergic genes
Clinical and genetic features of antidepressant induced mania in bipolar disorder
Social adjustment of remitted Bipolar and Unipolar out-patients. A comparison with age- and sex-matched controls
Br. J. Psychiatry
Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei
Synapse
Sleep deprivation hastens the antidepressant action of fluoxetine
Eur. Arch. Psychiatry Clin. Neurosci.
Ongoing lithium treatment prevents relapse after total sleep deprivation
J. Clin. Psychopharmacol.
Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression
Am. J. Psychiatry
Early experience and serotonin transporter gene variation interact to influence primate CNS function
Mol. Psychiatry
Complete coding sequence of human tryptophan hydroxylase
Nucleic Acids Res.
Cited by (115)
Pharmacogenomics in psychiatric diseases
2023, Pharmacogenomics: from Discovery to Clinical ImplementationThe genetics of selective serotonin reuptake inhibitors
2012, Pharmacology and TherapeuticsComplex interaction of circadian and non-circadian effects of light on mood: Shedding new light on an old story
2012, Sleep Medicine ReviewsThe neurobiology of the EEG biomarker as a predictor of treatment response in depression
2012, NeuropharmacologyCitation Excerpt :Various parameters of genetics, proteomics, metabolics, neuroendocrinology, neuroimaging, neurophysiology, and clinical characteristics have been suggested as potential biomarkers of antidepressant treatment outcome. For example, functional polymorphisms in genes of monoaminergic pathways such as those in the serotonin (5-HT) system have been shown to be predictive of outcome to selective serotonin reuptake inhibitor (SSRI) treatment (McMahon et al., 2006; Serretti et al., 2005). Recent studies employing the combined dexamethosone/corticotrophin releasing hormone test have demonstrated that hypothalamic–pituitary–adrenal axis activity can also predict the efficacy of antidepressant medication in patients with MDD (Ising et al., 2007; Paslakis et al., 2010; Schule et al., 2009).
Genetic differences in temperament determine whether lavender oil alleviates or exacerbates anxiety in sheep
2012, Physiology and BehaviorAssociation between serotonin transporter gene promoter-region polymorphism and 4- and 12-week treatment response to sertraline in posttraumatic stress disorder
2012, Journal of Affective DisordersCitation Excerpt :No explanation for this interracial variation has been proven, and it is possible that gene–gene or gene–environment interactions may be involved. The 5HTTLPR polymorphism however accounts for only 5–7% of the variance in the antidepressant response to SSRIs (Serretti et al., 2005). With this background, we conducted what we believe to be the first study of the influence of 5HTTLPR polymorphisms on PTSD outcomes following treatment with an SSRI.